Explore the Global GLP-1 Receptor Agonist Market — Analysis of Key Trends, Regional Growth, Top Players, and a 10-Year Forecast from 2026 to 2036

Future Market Insights

GLP-1 Receptor Agonist Market

Key Insight

GLP-1 receptor agonist sales will grow through 2036, led by exenatide at 24.4% share of the drug segment in 2025. Diabetes leads the indication segment as physicians continue prescribing GLP-1 therapies. The market is expected to reach USD 2.9 billion in 2026 and USD 7.8 billion by 2036.

May 15, 2026

Anurag Sharma

315 Pages

Cite this Report

GLP-1 Receptor Agonist Market

https://www.futuremarketinsights.com/reports/glp-1-receptor-agonist-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Amgen
BlackRock
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Innovent Biologics
Novo Nordisk A/S
PegBio Co. Ltd
The Vanguard Group
L'Oréal
Sun Pharmaceutical Industries Ltd

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

GLP-1 Receptor Agonist Market

Key Players

Similar Industry Reports